A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

Key Points

• Ventricular dysfunction improves with trandolapril treatment after myocardial infarction, showing promising cardiac outcomes.
• A significant reduction in cardiovascular events is noted with this angiotensin-converting-enzyme inhibitor.
• Clinical trial assessing the effectiveness of trandolapril in improving heart function after heart attacks.
• Implications highlight the need for angiotensin-converting-enzyme inhibitors in post-myocardial infarction care.

Abstract